Cancer Research UK's L333M R&D spend
Cancer Research UK has broken its record for research spending, according to its annual report and accounts. The charity spent L333.0 million ($597.3 million) on R&D in fiscal 2007/2008, a 6% increase on the previous year.
An additional L11.0 million was spent on cancer information and advocacy. Cancer Research UK funds over 4,500 research scientists, doctors and nurses throughout the country.
The group's chief executive, Harpal Kumar, said: "over the past year our ground-breaking research has continued to lead the way in the causes, prevention, diagnosis and treatment of every type of cancer." He added that "tens of thousands of lives have been saved in the UK and the improved survival rates we are now seeing for many types of cancer are proof that cancer research delivers results."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze